Home > Dermatology > Unresolved needs for patients with PsA despite growing therapeutic options

Unresolved needs for patients with PsA despite growing therapeutic options

Conference
WPPAC 2021
The multinational 2020 UPLIFT survey of patients with psoriatic arthritis (PsA) saw a greater proportion of patients receiving systemic treatment compared with the 2012 MAPP survey, and yet three-quarters of patients in UPLIFT considered their disease moderate-to-severe. On top of that, only half of patients reported seeing a healthcare provider in the past year. Hence, there is an unmet need to better manage persistent disease [1]. Patients with PsA experience a high disease burden and a wide range of comorbidities that negatively impact their health-related quality of life [2]. The 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey assessed the impact of psoriasis and PsA on patients [3]. MAPP results revealed a high patient-reported disease burden –measured by quality of life, work productivity, and treatment burden– and significant impact of PsA on physical function and the need for improved treatment.


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on